WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Total Liabilities : $1,829 Mil (As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Total Liabilities?

WuXi Biologics (Cayman)'s Total Liabilities for the quarter that ended in Jun. 2023 was $1,829 Mil.

WuXi Biologics (Cayman)'s quarterly Total Liabilities increased from Jun. 2022 ($1,791.23 Mil) to Dec. 2022 ($1,915.07 Mil) but then declined from Dec. 2022 ($1,915.07 Mil) to Jun. 2023 ($1,828.82 Mil).

WuXi Biologics (Cayman)'s annual Total Liabilities increased from Dec. 2020 ($1,233.19 Mil) to Dec. 2021 ($1,778.29 Mil) and increased from Dec. 2021 ($1,778.29 Mil) to Dec. 2022 ($1,915.07 Mil).

WuXi Biologics (Cayman) Total Liabilities Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Total Liabilities Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

671.00

1,233.19

1,778.29

1,915.07

1,758.75

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial													1,778.29	1,791.23	1,915.07	1,828.82	1,758.75

WuXi Biologics (Cayman) Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

WuXi Biologics (Cayman)'s Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1336.632	+	(423.308	+	155.132
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,915

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	7109.369	-	5194.297
	=	1,915

WuXi Biologics (Cayman)'s Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1136.768	+	(539.068	+	152.984
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,829

Total Liabilities	=	Total Assets (Q: Jun. 2023 )	-	Total Equity (Q: Jun. 2023 )
	=	7280.871	-	5452.051
	=	1,829

WuXi Biologics (Cayman) Total Liabilities Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXXWY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

WXIBF:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany 1FW2:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.